| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 543 | 2014 |
| Sugar and fat–that's where it's at: metabolic changes in tumors CD Young, SM Anderson Breast Cancer Research 10 (1), 1-9, 2008 | 203 | 2008 |
| Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo CD Young, AS Lewis, MC Rudolph, MD Ruehle, MR Jackman, UJ Yun, ... PloS one 6 (8), e23205, 2011 | 199 | 2011 |
| Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies AB Hanker, AD Pfefferle, JM Balko, MG Kuba, CD Young, V Sánchez, ... Proceedings of the National Academy of Sciences 110 (35), 14372-14377, 2013 | 197 | 2013 |
| Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution JC Stanford, C Young, D Hicks, P Owens, A Williams, DB Vaught, ... The Journal of clinical investigation 124 (11), 4737-4752, 2014 | 135 | 2014 |
| HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation DB Vaught, JC Stanford, C Young, DJ Hicks, F Wheeler, C Rinehart, ... Cancer research 72 (10), 2672-2682, 2012 | 133 | 2012 |
| Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 23 (20), 6138-6150, 2017 | 127 | 2017 |
| Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells KE Gomez, FL Wu, SB Keysar, JJ Morton, B Miller, TS Chimed, PN Le, ... Cancer Research 80 (19), 4185-4198, 2020 | 122 | 2020 |
| Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ... Science translational medicine 9 (402), 2017 | 121 | 2017 |
| Role of Ptc2 type 2C Ser/Thr phosphatase in yeast high-osmolarity glycerol pathway inactivation C Young, J Mapes, J Hanneman, S Al-Zarban, I Ota Eukaryotic cell 1 (6), 1032-1040, 2002 | 104 | 2002 |
| Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified breast cancers MM Joly, DJ Hicks, B Jones, V Sanchez, MV Estrada, C Young, ... Cancer research 76 (16), 4752-4764, 2016 | 103 | 2016 |
| Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts X Shi, CD Young, H Zhou, XJ Wang Biomolecules 10 (12), 1666, 2020 | 101 | 2020 |
| The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium JM Balko, TW Miller, MM Morrison, K Hutchinson, C Young, C Rinehart, ... Proceedings of the National Academy of Sciences 109 (1), 221-226, 2012 | 83 | 2012 |
| ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis RS Cook, JT Garrett, V Sánchez, JC Stanford, C Young, A Chakrabarty, ... Cancer research 71 (11), 3941-3951, 2011 | 76 | 2011 |
| Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer SD Karam, K Reddy, PJ Blatchford, T Waxweiler, AM DeLouize, A Oweida, ... Clinical Cancer Research 24 (20), 4949-4959, 2018 | 75 | 2018 |
| Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis MM Joly, MM Williams, DJ Hicks, B Jones, V Sanchez, CD Young, ... Breast Cancer Research 19 (1), 1-15, 2017 | 74 | 2017 |
| ErbB3 downregulation enhances luminal breast tumor response to antiestrogens MM Morrison, K Hutchinson, MM Williams, JC Stanford, JM Balko, ... The Journal of clinical investigation 123 (10), 4329-4343, 2013 | 66 | 2013 |
| mTOR directs breast morphogenesis through the PKC-alpha-Rac1 signaling axis MM Morrison, CD Young, S Wang, T Sobolik, VM Sanchez, DJ Hicks, ... PLoS genetics 11 (7), e1005291, 2015 | 53 | 2015 |
| Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3 CD Young, EC Nolte, A Lewis, NJ Serkova, SM Anderson Breast Cancer Research 10 (4), 1-12, 2008 | 42 | 2008 |
| An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression LJ Schwarz, KE Hutchinson, BN Rexer, MV Estrada, PI Gonzalez Ericsson, ... JNCI: Journal of the National Cancer Institute 109 (11), djx065, 2017 | 39 | 2017 |
